- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
1. **Financial Performance**: In Q3 FY25, SeQuent Scientific reported consolidated revenues of INR 3,908 million, marking an 18.7% year-on-year increase, the highest for any quarter in three years. Overall, revenue for the first nine months increased by 14% to INR 11,497 million. EBITDA for Q3 grew 63.8% to INR 494 million, resulting in an EBITDA margin (pre-ESOP) of 12.6%, up 340 basis points compared to the previous year. Profit Before Tax (PBT) soared by 444% to INR 81 million. For the nine months, cumulative PBT reached INR 280 million, reflecting nearly 150% growth.
2. **Future Outlook and Growth Drivers**: Management emphasized strong growth prospects, particularly in emerging markets like Turkey and expanding operations into Mexico and Peru. The strategic merger with Viyash Life Sciences is anticipated to enhance R&D capabilities and drive growth in animal health products.
3. **Order Book and Operational Updates**: Management discussed efforts in the formulations segment, specifically the successful introduction of new products in Europe and Turkey, and the growth of the API business, primarily in deworming. The consolidation of operations and the closure of high-cost facilities are expected to optimize efficiency and increase margins.
4. **Analyst Q&A Insights (Detailed)**:
- **Revenue and Profitability**: Analysts sought clarity on growth drivers in emerging markets. The focus is on product mix, pricing, and geographical expansion, particularly from Turkey.
- **Market Position and Competitive Landscape**: Analysts probed about margin improvements across segments, to which management attributed gains to optimized pricing and product mix.
- **Operational Challenges or Risks**: Questions regarding supply chain issues were addressed, with assurance that current geopolitical conditions are monitored.
- **Capex and Capital Allocation**: Discussions on capital expenditures included plans for continued investment in operational efficiency and growth, backed by a strong balance sheet.
- **Strategic Priorities and Long-Term Vision**: Analysts inquired about long-term growth targets, with management highlighting double-digit growth expectations fueled by recent initiatives.
5. **Market or Regulatory Updates**: Regulatory approvals for the merger with Viyash are proceeding positively, with expectations for completion in the near term, allowing for integration synergies and enhanced market positioning.
6. **Strategic Focus Areas**: Key strategic themes include an emphasis on innovation, market expansion, and margin improvement through cost controls. Management's confidence in future performance was apparent throughout the discussion.
7. **Investor Insight**: The strong financial performance and positive outlook, combined with strategic growth initiatives and operational efficiencies, suggest alignment with a ‘buy’ position for keen investors. However, ongoing geopolitical and market dynamics warrant caution, reinforcing the need for close monitoring.